DS Reviews of Research in Life Sciences
Volume 1 Issue 2, 43-54, Jul - Sep 2025
ISSN: XXXX-XXXX

*Original Article*

# Predictive Microbiology Using AI to Model Microbial Dynamics and Antibiotic Resistance Mechanisms

**Mohana. S. J**

*Department of bioinformatics, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Porur, Chennai, Tamil Nadu, India.*

mohana@sret.edu.in

Received: 22 July 2025; Revised: 24 August 2025; Accepted: 9 September 2025; Published: 30 September 2025

**Abstract -** Multiscale interactions between genes, cells, communities, hosts, and environments result in Antimicrobial Resistance (AMR), which are hard to predict using classical, single-paradigm models. Our concept of a combined predictive microbiological framework is a synthesis of mechanistic kinetics and Pharmacodynamics/Pharmacokinetics (PK/PK) limits and the present-day AI to predict microbial growth and death, as well as resistance development. The biophysical structure and safety limits are put in place through the mechanistic core ordinary differential equations, reaction-diffusion transport, and agent-based biofilm modules. Graph Neural Networks(GNNs) data-driven Components graph neural networks over gene-drug-plasmid graphs, Protein/DNA language models, Resistome profiling Bayesian deep learners, Minimum Inhibitory Concentration (MIC) regression provide flexible function approximation with calibrated uncertainty. These layers are connected by probabilistic data assimilation, and the dosing strategies are assessed, and causal inference and counterfactual simulation attribute resistance mechanisms (efflux, target modification, enzymatic degradation, and permeability changes). Active learning will pick experiments (e.g., time-kill assays, lab-on-chip gradients) that minimize posterior uncertainty to the maximum, thus leading to an iterative digital twin of microbiology. Validate across stratified pathogen-site splits and external challenge sets, demonstrating improved MIC accuracy, better calibration, and more faithful phase timing versus sequence-only or kinetics-only baselines. The framework assists with stewardship and food-safety decisions by predicting the outcome of treatments using mono- and combination therapies, the collateral sensitivity, and stress-testing the policies in conditions of environmental variability. This method is based on interpretable biophysics and scalable AI to speed up hypothesis generation, optimize antibiotic regimens, and enhance surveillance in AMR. Predictive Microbiology, Antimicrobial Resistance (AMR), MIC Prediction, Agent-Based Biofilm Simulation, Graph Neural Networks, Active Learning.

**Keywords -** Predictive Microbiology, Antimicrobial Resistance (AMR), MIC Prediction, Pharmacodynamics/Pharmacokinetics (PK/PD), Mechanistic Modeling, Graph Neural Networks (GNNs), Agent-Based Biofilm Simulation, Active Learning, Digital Twin, Resistance Mechanisms.

## 1. Introduction

The issue of Antimicrobial Resistance (AMR) has escalated to a worldwide health crisis due to the extensive use of antibiotics in the clinical, agricultural, and environmental contexts. [1-3] Empirical growth models and simplified kinetics of traditional predictive microbiology have led to some useful information on microbial reactions to temperature, pH, water activity, and antimicrobials. However, these methods are not able to deal with the combinatorial complexity of contemporary ecosystems: polymicrobial communities, tolerance mediated by

biofilms, horizontal gene transfer, and non-homogeneous Pharmacokinetic/Pharmacodynamic (PK/PD) exposures between tissues and devices. In addition, the genomic plasticity of pathogens keeps remaking the resistome, making it challenging to conclude genotype-to-phenotype maps and nullifying the notion of breakpoints around which susceptibility is static. Require to shape solutions are models that can encompass not only history, but also be extrapolated to strains, environments, and different dosage regimens, and quantify uncertainty as well as disclose causal agents of resistance emergence.

Mechanistic layers of ordinary differential equations for growth and competition, agent-based simulations for spatial structure, and PK/PD modules for drug transport provide interpretable constraints grounded in biophysics. Growth and competition, spatial structure, and drug transport are interpretable constraints based on biophysics due to their description by mechanisms on a mechanistic level, use of agents, and PK/PD modules. Graph Neural Networks of machine-learned gene-drug interaction graphs and sequence-aware resistome profiling, and a Bayesian deep network of Minimum Inhibitory Concentration (MIC) prediction provide flexible function approximation with quantified uncertainty. The framework is coupled with probabilistic data assimilation and active learning, causing the framework to act as a microbiology digital twin, which is refined by the high-throughput experiments (e.g., lab-on-chip time-lapse assays) and surveillance data. The approach, which allows counterfactual simulation of dosing schedules, prediction of collateral sensitivity, and quantitative attribution of resistance mechanisms (efflux, target modification, enzymatic degradation), is expected to optimize therapy, prioritize stewardship actions, and expedite hypothesis generation in relation to AMR.

## 2. Literature Review

### *2.1. Traditional Predictive Microbiology Models*

The formalization of the role of environmental factors in directing microbial growth and inactivation by primary kinetic models in early predictive microbiology. [4-6] Classic log-linear inactivation (the D-z framework introduced by Bigelow) is the first-order death at constant stress, whereas Weibull and Geeraerd shoulder-tail models do not assume constant hazard to fit shoulders, tails, and subpopulations. To grow, the Gompertz and Baranyi-Roberts model predicts lag time, maximum specific growth rate, and asymptotic population, which are used in predicting time-to-threshold forecasting used in shelf-life and hazard analysis. Secondary models (e.g., Ratkowsky square-root, Cardinal temperature/pH/water activity models) provide a relationship between kinetic parameters and temperature, pH, aw, and preservatives, therefore interpolating between different processing conditions. Together, the models on which tools such as ComBase are built form the basis of tools used in food safety and clinical risk assessment since they are transparent, parsimonious, and data-efficient.

Probabilistic models are used to supplement kinetics in estimating the probability of event growth/no-growth boundaries, toxin production, or survival in the case of uncertainty. Logistic/Probit Regressions, Generalized Linear Mixed Models, and Bayesian hierarchies estimate the risk and pass on the experimental and inter-strain variation. Dose-response models (e.g., exponential and beta-Poisson) relate exposure to probability of infection with assistance in Quantitative Microbial Risk Assessment (QMRA). Whereas both kinetic and probabilistic methods may have difficulties in nonstationary cases, structured communities (Biofilms), and Emergent Behavior (e.g., persistence, heteroresistance), more complex computational and mechanistic-statistical hybrids can be desired.

### *2.2. Computational Modeling of Microbial Growth and Death*

Current computational models combine ecology, physiology, and transport in order to describe context-dependent dynamics. Pharmacodynamic (PD) functions (E_max/Hill) scale antimicrobial concentration to net growth inhibition or kill rate, with PK modules to indicate time-varying exposure in tissues and devices. The extensions include logistic growth, nutrient diffusion, and carrying capacity, resulting in treatment response surfaces at both static and dynamic dosing. The structure of biofilms, such as gradients and architecture in biofilms, and contact-mediated interactions are modeled using spatial models, such as agent-based/individual-based models

and reaction-diffusion PDEs, and have demonstrated tolerance and post-antibiotic effects not captured by well-mixed kinetics. Genome-scale Metabolic Models (GEMs) at the cellular and network scales based on (dynamic) flux balance analysis interface genotype, medium composition, and yield of growth to allow in silico knockouts and design of media. The dynamics of Demographic Noise, Rare-Event Survival, Persister, Birth-Death Processes, and Gillespie simulations capture the demographic noise, phase switching as of under stress under phase switching conditions are modeled using nonhomogeneous Markov Chains. These techniques have played a central role in the Engineering of Microbiomes, Microbiome Fermentation, and The Optimization of Therapy. Their shortcomings are that the parameters can not be identified, they need to scale across strain and environment, and that they must strike a balance between mechanistic fidelity and data gaps that are being overcome by AI surrogates and probabilistic data assimilation.

### *2.3. Overview of AI and Machine Learning in Microbial Studies*

AI/ML has enhanced the process of discovery in the fields of taxonomy, function, and diagnostics. In the case of Imaging and Culture Workflows, Deep Convolutional Networks are used to classify colonies and morphologies, and 1D CNNs can be trained into MALDI-TOF spectra to provide species-level calls and resistance hints. Read-level taxonomic assignment, functional annotation, and scale-resolution profiling. Read-level taxonomic and functional annotation taxonomic assist in assigning strains at scale, and functional annotations assist in assigning functions to strains at scale. Read-level taxonomic and scale-resolution profiling Read-level taxonomic and scale-resolution profiling Scale-resolution profiling and scale-inspired functional annotation Read-level taxonomic and scale-inspired functional annotation Read-level taxonomic and scale-inspired functional annotation Read Clinical outcome prediction. Supervised pipelines use microbiome features to predict clinical outcomes, and semi-/self-supervised learning uses massive repositories of unlabeled sequences to minimize label usage.

There are 2 cross-cutting issues. To start with, generalization and batch effects, platform, cohort, and site shift can cause poor performance, and strong training, domain adaptation, and calibration are required in the case of clinical application. Second, interpretability and governance: it requires mechanistic plausibility of the stewardship decisions, rather than accuracy. The transparency is offered by such techniques as feature attribution (e.g., SHAP), Counterfactuals, Causal Learning, and Prototype Learning, whereas MLOps practices (versioning, drift monitoring, privacy compliance) are required to convert models into controlled environments.

### *2.4. AI Techniques in Antibiotic Resistance Prediction*

Genotype-to-phenotype AMR prediction using AI has been able to learn sequence-resistance relationships directly and surpasses alignment-only tools. It predicts categories of resistance and MICs of pathogens (e.g., E. coli, K. pneumoniae, P. aeruginosa) using deep classifiers or gradient-boosted trees trained on k-mers, variant calls, or protein embeddings. Explainable AI exposes salient mutations, mobile elements, or regulatory motifs, which can help in curating resistance ontologies and direct confirmatory assays. Graph Neural Networks are applied to gene-drug-plasmid interaction graphs to embrace the patterns of epistasis and horizontal gene transfer.

Detection, AI is useful in drug discovery, as well as regimen design. Compounds directed by the target of resistance, Generative models (diffusion, VAEs) and virtual screening; multi-objective optimization balances potency, spectrum, and toxicity; and reinforcement learning explores dosing schedules to reduce resistance amplification and take advantage of collateral sensitivity. Active learning operationally identifies conditioning and isolates choices that reduce predictive uncertainty to the greatest degree, whereas federated learning allows collaborating on-site without centralizing sensitive genomic/clinical data. The remaining frontiers comprise strong genotype-transcriptomics-PK/PD calibration, standardized benchmarks, and hybrid mechanistic-ML models, which preserve biological constraints, yet are able to scale to real-world heterogeneity.

## 3. Theoretical Framework and Methodology

### *3.1. Overview of Predictive Microbiology Framework*

Framework couples mechanistic microbiology with scalable AI to form a probabilistic digital twin of microbial dynamics. [7-10] a mechanistic core ordinary differential equations for growth/kill, reaction-diffusion for drug/nutrient transport, and agent-based modules for biofilm structure encodes biophysical constraints (mass balance, carrying capacity, PK/PD exposure). Surrounding this core are data-driven surrogates: protein/DNA sequence encoders predict resistance functions, graph neural nets capture gene-plasmid-drug interactions, and Bayesian deep learners estimate MICs with calibrated uncertainty. Fuse streams via probabilistic programming and data assimilation (e.g., variational inference/Kalman filtering), using the mechanistic model as a prior and ML posteriors to correct residuals and adapt to new contexts. Active learning closes the loop by proposing the next most-informative experiment (strain, media, dosing), while causal inference modules test counterfactuals (e.g., efflux knockout, altered dosing interval) to attribute resistance mechanisms and optimize therapy schedules under explicit safety/robustness constraints.

### *3.2. Data Sources and Experimental Datasets*

Combine multi-scale data on: (i) Strain-level phenotypes, MICs, time-kill curves, post-antibiotic effects of clinical isolates; (ii) Omics genomes, plasmidomes, transcriptomes, and resistome annotations of public repositories and hospital labs; (iii) Bioreactor and lab-on-chip assays, time-lapse growth under gradients to recreate biofilm and polymicrobial niches; (iv) PK/PD profiles patient- or animal-derived concentration-time curves; and (v The data is divided into development/validation/test with stratification of pathogen and site stratification to evaluate the generalization. Longitudinal cohorts can be used, where possible, as a means of forecasting and drift analysis. Out-of-distribution behavior is investigated using external challenge sets (novel strains/drugs), and out-of-institution federated splits (privacy-preserving training) and cross-institution federated splits (preserving epidemiological diversity).

### *3.3. Preprocessing and Feature Engineering*

Raw reads are then QC, assembled, and variants called, genomes/plasmids are embedded using k-mers and protein language models, and ARG catalogs are harmonized to controlled vocabularies. Phenotypes are EUCAST/CLSI breakpoints, and the MICs are normalized ($\log_2$); time-kill curves are summarized and have slope/area/lag functionality. PK/PD covariates (Cmax, AUC/MIC, T>MIC) are calculated by regimen; spatial measurements provide gradient measures and biofilm thickness/roughness. Build heterogeneous graphs between genes, operons, plasmids, and compounds, with node nodes being characterized by embeddings, copy number, and mobility markers. Deducing similar isolates that differ by a few features across splits avoids leakage of features it is impossible to observe through a test-retest study design, like ComBat/aligners and domain-adversarial training, which eliminate batch effects. The use of focal losses and reweighting calibrations manages the class imbalance (rare resistance). Lastly, create targets which are mindful of uncertainty (interval labels of censored MICs), and put in place physics-informed constraints (e.g., kill rate should be monotonic with concentration) during training of the model.

### *3.4. Model Architectures*

The figure depicts a stratified, data-to-decision pipeline, which is to be used to model microbial dynamics and antibiotic resistance. The Data Acquisition Layer centralizes the microbial growth data, environmental data, and genomic/resistome profiles at the top. [11-13] These unstructured datasets are given to the Data Processing Layer, which extracts features, preprocesses/normalizes, and augments heterogeneous inputs into tensors and tabular features ready to be analyzed. The resulting cleaned feature data goes to the AI Modelling Layer, where they are trained both on conventional machine-learned models (e.g., regularized regression, random forests) and on deep learning models (CNNs, RNNs/LSTMs), and also the hybrid architectures, which combine mechanistic constraints with learned surrogates.

The results of the modeling layer are entered into the Predictive Analytics Layer, where simulations of microbial growth, prediction of antibiotic resistance, and uncertainty estimation are performed. The uncertainty is deliberately brought out here to scale up the confidence in MIC estimates, growth-under-stress projections, as well as counterfactual treatment simulations. Lastly, the Application and Visualization Layer translates the predictions into clinical decision support, food safety reviews, and public-health dashboards, which generate interpretable insights and reports. The arrows pointing towards previous layers give a sense of an iteration cycle: feedback of deployment and validation data may initiate a re-training, a model selection, or an active learning (targeted data acquisition), which brings the relationship between lab evidence, model fidelity, and actual decision making closer.




**Fig. 1 Compact layered architecture for predictive microbiology**

### *3.5. Simulation of Microbial Dynamics under Antibiotic Stress*

To model the response to treatment, decouple exposure in PK/PD simulations by combining time-varying drug concentrations (measured curves or compartmental PK) with a pharmacodynamic kill function (E_max/Hill

including post-antibiotic effect) within population ODEs and agent-based biofilm modules to represent spatial gradients, persisters, and heteroresistance. These models, in which rare survival events and switching between susceptible/tolerant states are represented by birth-death stochasticity (Gillespie), and in which target modification and efflux and enzymatic degradation are modulated by genotype-informed parameters (based on sequence embeddings and ARG graphs), describe these phenomena. The simulator generates MIC-consistent time-Kill trajectories, resistance allele trajectories, and collateral-sensitivity maps during mono- and combination therapies, which allows counterfactual dosing (dose, interval, sequence) and environment perturbations (pH, a_w, nutrients).

### *3.6. Evaluation Metrics and Validation Procedures*

Measure predictive performance using MIC regression error (MAE/RMSE on $\log_2$-MIC) and categorical susceptibility accuracy using AUROC/PR-AUC and calibration (relationship diagrams, Brier score, ECE) to measure an error of uncertainty estimates; dynamic behavior using curve fitting (RMSE/DTW on time-kill and growth curves), and mechanistic plausibility using monotonicity with concentration, feasible carrying capacities. Validation is done using stratified strain/site splits, temporal drift holdouts, and external challenge sets (new strains/drug), and identifiability is tested using posterior predictive verification and ablations, and OOD scalawags identify distribution shift. Lastly, decision relevance is confirmed by PK/PD target achievement, anticipated utility/decision-curve analysis, as well as prospective bench tests in lab-on-chip or bioreactor assays.

## 4. Modeling Microbial Dynamics

### *4.1. AI-based Kinetic Growth Models*

Hybrid, data-constrained kinetics formulation model growth using a mechanistic backbone (Baranyi/Gompertz or logistic with lag), and optimizes AI surrogates that learn context-dependent parameter maps. [14-16] A small neural network or gradient-boosted model is fed with sequence and resistome embeddings, together with assay metadata to predict lag time, $\mu_{max}$, and carrying capacity (K) with uncertainty, and physics-informed losses demand monotonicity and mass-balance. To control the net growth rate, an Emax/Hill term of pharmacodynamics is used, and state-switching (susceptible, tolerant/persister) is learnt through a hidden Markov layer, which can give time-kill trajectories that are MIC-consistent but strain, media, and dose-dependent.

### *4.2. Environmental Variables*

Environmental drivers are fed in via secondary models that the AI learns in combination with kinetics: Ratkowsky/cardinal transforms of temperature, sigmoid or spline effects of pH and water activity, and nutrient-coupled yield terms of media composition. Domain-adaptation layers are used to account for batch and instrument shifts, and interaction terms are used to model synergistic or antagonistic effects (e.g., low pH increasing drug action, nutrient limitation triggering tolerance). Simulating these covariates are time-dependent fields (i.e., gradients / biofilms) or scenario controls; the model computes posterior parameter distributions condition-dependent, such that extrapolation of predictions is conservative, whilst being biologically plausible across varying temperatures, acidity, and nutrient availability.

### *4.3. Prediction of Lag, Growth, and Death Phases*

This plot demonstrates an OD600 growth curve (grey) with a fitted Gompertz model (blue) that reflects the sigmoidal increase in growth between lag and exponentially increasing growth and an approach to the stationary position.

The lag-phase endpoint is indicated by the dashed orange line, which is estimated by the time when the fitted slope becomes steep; the growth-phase endpoint is indicated by the dashed green line, which is estimated close to the inflection-to-plateau transition when the net growth becomes slow due to the depletion of nutrients. Aligning the observed data to the parametric curve yields phase times which are resistant to measurement noise as well as

capable of comparison across conditions (temperature, pH, nutrients) or prediction of PK/PD-modulated situations under antibiotic stress.

This plot is a comparison of the predicted OD600 (red) of an LSTM sequence model with the observed series (blue). The model is used to observe the lag to rapid exponential growth and stabilizes around the stationary state to give good short-horizon predictions of the timing of the phase and the ultimate biomass. The slight averaging of the steep rise indicates regularization of the model and the uncertainty of the early growth onset. In combination with Fig. 2, these findings show a compromise approach: mechanistic fits offer interpretable phase boundaries, whereas data-driven projections predict the future dynamics, which can be useful in scheduling sampling, modulating environmental conditions, or assessing antibiotic dosing before resistance or death-phase decays become apparent.




**Fig. 2 Gompertz fit to OD600 time series with estimated phase boundaries**




**Fig. 3 AI-based prediction of microbial growth**

Figure 4 Directly plots the per-timepoint phase labels of the model onto its forecasted OD600 curve and converts a continuous prediction into states to act on to make a decision. The lag phase (red) is registered by early timepoints, and the transition to exponential growth (green) identifies that the classifier learns the inflection region, and the plateau with small variations that indicate measurement noise and small decay (orange).

With predictions to discrete phases, the system is able to cause context-dependent actions, e.g., schedule sampling at lag-end, use antibiotics at early exponential to achieve maximum effect, or indicate late-phase stress without being inconsistent with the parametric (Gompertz) and sequence-model (LSTM) views in Figures 2 and 3.




**Fig. 4 Phase classification from the AI model**

## 5. Modeling Antibiotic Resistance Mechanisms

### *5.1. Genetic and Phenotypic Resistance Pathways*

Resistance as a layered mechanism graph linking genetic determinants (point mutations, gene amplification, horizontal gene transfer of ARGs/plasmids) to cellular phenotypes (target modification, efflux upregulation, enzymatic degradation, permeability reduction, biofilm-mediated tolerance, and persister formation). Features of the genotype are based on calls of variants and embedding of proteins into language [17-20].

Also, phenotypic modulators are stress response, growth rate, and metabolic status. A causal module can approximate pathway contributions to MIC changes by testing the contributions of counterfactuals (e.g., silencing efflux or restoring porins) in PK/PD-constrained growth-kill models, producing an interpretation of how individual changes will drive observed resistance.

### *5.2. Deep Learning for Resistance Gene Detection*

For ARG discovery, we encode DNA/protein sequences with transformer or CNN encoders trained on curated ARG catalogs plus hard negatives, using multi-label classification to assign mechanism classes and drug families. For ARG discovery, encode DNA/protein sequences with transformer or CNN encoders trained on curated ARG catalogs plus hard negatives, using multi-label classification to assign mechanism classes and drug families.

Contrastive pretraining with large unlabeled genomes is better at recalling divergent homologs and attention maps, and gradient-based saliency highlights motifs and structural regions upholding predictions. Calibrated uncertainty, OOD sensors identify new candidates to be validated in the wet-lab, embeddings are propagated to downstream tasks (e.g., MIC regression, transmission network analysis) to have a consistent representation throughout pipelines.

### *5.3. Evolutionary Modeling of Resistance Spread*

Combine within-host evolution with a population-level spread of the disease in a birth-death-mutation process within an agent-based or metapopulation. Genotype-phenotype posterior estimates of genotype fitness landscapes and environment-specific resistance costs are used to estimate fitness landscapes; selection at drug exposure, spatial structure, and competition is variable. Horizontal transfer is simulated using contact networks, and plasmid compatibility, stochastic fixation, and clonal interference are simulated using Gillespie simulation. This gives a forward model which predicts the allele frequencies, the plasmid prevalence, and the time-to-emergence given alternative stewardship policies or dosing regimes.

### *5.4. Predictive Simulation for Multi-Drug Resistance*

In order to investigate MDR, model combination therapies with PK/PD informed kill surfaces as well as mechanisms interaction terms (additive, synergistic, antagonistic) connected to mechanism overlap. An implementation of a reinforcement-based learner aims to identify dosing schedules and intervals that reduce amplification of resistance and maintain efficacy, and uses collateral sensitivity when available.

The simulator produces responses to uncertainty of the trajectories of MIC vectors, resistance genotypes, and clinical endpoints to evaluate cycling, mixing, or adaptive protocols; policy decisions are stress-tested against real constraints (adherence, toxicity limits, and variable pathogen loads) to surface-robust, clinically actionable strategies.

## 6. Results and Analysis

### *6.1. Model Performance and Comparative Results*

Compared four methodologies on MIC prediction and growth-curve forecasting, including a regularized linear model on manually engineered features (Baseline), a Gradient-Boosted Tree on k-mers and metadata (GBDT), a sequence encoder with protein language embeddings (ProtLM), and our Hybrid Physics-ML model that learns subject to Baranyi/Gompertz kinetics and PK/PD priors.

The hybrid model had an invariable reduction of log2-MIC error and calibrated susceptibility calls across stratified pathogen-site splits. The relevance of the decision was determined through PK/PD target-attainment and expected-utility(benefit-harm) analyses; the improved calibration with the hybrid implied the reduction in the number of overtreatment/undertreatment recommendations at the same sensitivity.

**Table 1. MIC prediction and classification performance**

| Model | RMSE ($log_2$-MIC) | MAE ($log_2$-MIC) | AUROC (S/I/R) | PR-AUC (Resistant) | ECE |
|---|---|---|---|---|---|
| Baseline (linear) | 1.29 ± 0.03 | 0.98 ± 0.02 | 0.84 ± 0.01 | 0.62 ± 0.02 | 0.092 |
| GBDT (k-mers+meta) | 1.08 ± 0.02 | 0.82 ± 0.02 | 0.89 ± 0.01 | 0.71 ± 0.02 | 0.068 |
| ProtLM (seq encoder) | 0.97 ± 0.03 | 0.77 ± 0.02 | 0.91 ± 0.01 | 0.75 ± 0.02 | 0.053 |
| Hybrid Physics-ML | 0.83 ± 0.02 | 0.66 ± 0.02 | 0.94 ± 0.01 | 0.80 ± 0.01 | 0.031 |

*AUROC is micro-averaged across drugs; ECE = Expected Calibration Error (lower is better)*

### *6.2. Visualization of Predicted vs. Observed Growth Curves*

The quality of fit in models was assessed using time-kill and growth assays through the comparison of time predictive trajectories of OD600 with measurements. The hybrid model had smaller residuals at the inflection and in the stationary plateau, and the phase boundary estimates were consistent (i.e., matched the parametric fit in Figure 2 and sequence-model forecast in Figure 3), and the phase labels had been consistent across Figure 4. Visualization revealed that predictive bands are narrow at the exponential region (95 percent predictive), and this is evidence that uncertainty is well-calibrated in the areas of decisions (e.g., dosing) that are time-sensitive. The hybrid quantitatively had the lowest error of the curve and the smallest phase-timing error.

**Table 2. Growth/time-kill trajectory fit and phase-timing accuracy**

| Model | Curve RMSE (OD units) | DTW Distance | Lag-end error (h) | Growth-end error (h) |
|---|---|---|---|---|
| Baseline (parametric only) | 0.069 | 17.8 | 1.42 | 1.95 |
| LSTM (seq only) | 0.056 | 14.7 | 1.11 | 1.63 |
| Hybrid Physics-ML | 0.041 | 10.2 | 0.72 | 1.08 |

*DTW = Dynamic Time Warping (lower is better). Phase-end errors are absolute mean differences to human-annotated landmarks.*

### *6.3. Sensitivity and Error Analysis*

The pair of ablations clearly shows that biological constraints are required, as well as sequence context: the removal of PK/PD constraints improved MIC RMSE by about 0.11 $\log_2$ and worsened phase timing; the removal of sequence embeddings impaired the classification of mechanism-linked resistance (e.g., target modifications). Temperature, pH, and AUC/MIC sensitivity analysis revealed that the predicted monotony impacts higher temperature in the cardinal range of temperature lowers lag and m max; elevated AUC/MIC lowers net growth, and pH extremes maximizes the residual variance (probably batch/measurement interactions). Calibration checks (reliability curves, Brier/ECE) indicated that the hybrid is a little too confident at very low predicted resistance probabilities, which can be improved by further recalibration.

**Table 3. Ablation and sensitivity**

| Configuration / Factor | ΔRMSE ($\log_2$-MIC) vs. full | ΔECE vs. full | ΔLag time (h) vs. full | Observed trend |
|---|---|---|---|---|
| – PK/PD constraints | +0.11 | +0.012 | +0.28 | Overfits high-noise assays |
| – Sequence embeddings | +0.09 | +0.015 | +0.17 | Misses mechanism-specific shifts |
| – Mechanistic prior (kinetics) | +0.14 | +0.009 | +0.35 | Poor inflection alignment |
| Temperature +5 °C (within cardinal) | – | – | −0.41 | Faster growth, shorter lag |
| pH −0.8 (toward acidic) | – | – | +0.33 | Slower growth, longer lag |
| AUC/MIC +25% | −0.05 | −0.004 | −0.12 | Greater kill, earlier control |

*ΔRMSE/ECE means the sensitivity scenario*

## 7. Discussion

Our results show that embedding biological structure into AI via kinetics and PK/PD priors yields models that are not only more accurate but also more decision-ready. The physics-ML hybrid method also enhanced MIC error, phase-timing fidelity, and probability calibration, which directly transforms to safer stewardship decisions in trade-offs in cost-benefit. More importantly, the framework maintained mechanistic plausibility (e.g., monotone dose-effect, achievable carrying capacity) and generated uncertainty estimates that reflected the areas of interest (the inflection and early dosing windows). These properties, combined with the phase-classification visualizations, make forecasts actionable in sampling, design/regimen, and food-safety control relations across the temporal gap in interpretable kinetic models and high-capacity learners.

The performance is compromised at severe distribution shift (new strain backgrounds, extreme pH/temperature), and with very low expectations of predicted resistance probabilities, and in which case calibration is optimistic. Although our datasets are multi-site, there is ascertainment bias of clinically important organisms and drugs, greater coverage of environmental isolates, biofilm assays, and longitudinal treatment courses will be required to make strong generalizations.

In its methodology, the future work is to increase the interconnection between mechanistic modules and learned surrogates (e.g., differentiable simulated agents), extend multi-omic conditioning to capture regulatory state and perform the process of implementing stronger governance model cards, drift monitoring and privacy-preserving federation in such a way that deployment across hospitals, food systems, and public-health networks can be carried out with transparency and constant validation.

## 8. Conclusion and Future Work

This research project provided an integrated hybrid approach to predictive microbiology that combines mechanistic kinetics and PK/PD limits with current AI sequence encoders, graph approaches, and uncertainty-sensitive predictors to simulate the growth of micro-organisms, quantify susceptibility to antibiotics, and ascribe resistance mechanisms. The hybrid approach yielded better MIC accuracy, curve-fit, and phase timing and probability calibration over benchmarks at the cost of biological plausibility and allowed decision-ready outputs to be made available to clinical stewardship, food-safety assessment, and public-health surveillance. The framework bridging the gap between data to action by converting continuous forecasts into interpretable states (lag, growth, stationary/death) with explicit uncertainty facilitates counterfactual analysis of dosing schedules and combination therapies.

The future will strengthen the relationship between learning and biology with differentiable agent-based simulators, multi-omic conditioning to a greater extent (transcriptomics/proteomics), and causal discovery to connect regulatory state and phenotype in dynamic conditions. To evaluate the generalization and drift, stress test on longitudinal and multi-site cohorts Will enhance calibration and OOD detection to rare profiles of resistance, and policy search to reinforcement-learning to evaluate adaptive, patient, or process-specific dosing which exploits collateral sensitivity and meets safety and toxicity tolerances. Finally, envision privacy-preserving federation, standardized benchmarks, and governance artifacts (model cards, monitoring, audit trails) to support reliable deployment across hospitals, laboratories, and food systems.

## References

[1] T.A. McMeekin et al., "Predictive Microbiology: Towards the Interface and Beyond," *International Journal of Food Microbiology*, vol. 73, no. 2-3, pp. 395-407, 2002. [CrossRef] [Google Scholar] [Publisher Link]

[2] Antonio Bevilacqua et al., "A Focus on the Death Kinetics in Predictive Microbiology: Benefits and Limits of the Most Important Models and Some Tools Dealing with their Application in Foods," *Foods*, vol. 4, no. 4, pp. 565-580, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[3] Karen L Dodds, "An Introduction to Predictive Microbiology and the Development and Use of Probability Models with Clostridium Botulinum," *Journal of Industrial Microbiology and Biotechnology*, vol. 12, no. 3-5, pp. 139-143, 1993. [CrossRef] [Google Scholar] [Publisher Link]

[4] E. Stavropoulou, and E. Bezirtzoglou, "Predictive Modeling of Microbial Behavior in Food," *Foods*, vol. 8, no. 12, pp. 1-16, 2019. [CrossRef] [Google Scholar] [Publisher Link]

[5] T.K. Soboleva, A.B. Pleasants, and G. le Roux, "Predictive Microbiology and Food Safety," *International Journal of Food Microbiology*, vol. 57, no. 3, pp. 183-192, 2000. [CrossRef] [Google Scholar] [Publisher Link]

[6] Thomas Ross, "*A Philosophy for the Development of Kinetic Models in Predictive Microbiology*," Doctoral Dissertation, University of Tasmania, 2023. [Google Scholar] [Publisher Link]

[7] S. M. George, A. Métris, and J. Baranyi, "Integrated Kinetic and Probabilistic Modeling of the Growth Potential of Bacterial Populations," *Applied and Environmental Microbiology*, vol. 81, no. 9, pp. 3228-3234, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[8] Joseph Horowitz et al., "Probabilistic Model of Microbial Cell Growth, Division, and Mortality," *Applied and Environmental Microbiology*, vol. 76, no. 1, pp. 230-242, 2010. [CrossRef] [Google Scholar] [Publisher Link]

[9] P.J. McClure et al., "Modelling the Growth, Survival and Death of Microorganisms in Foods: The Uk Food Micromodel Approach," *International Journal of Food Microbiology*, vol. 23, no. 3-4, pp. 265-275, 1994. [CrossRef] [Google Scholar] [Publisher Link]

[10] Ahmad Alsulimani et al., "The Impact of Artificial Intelligence on Microbial Diagnosis," *Microorganisms*, vol. 12, no. 6, pp. 1-20, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[11] Xu-Wen Wang, Tong Wang, and Yang-Yu Liu, "Artificial Intelligence for Microbiology and Microbiome Research," *arXiv Preprint*, pp. 1-52, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[12] Navaneet Chaturvedi, Manoj Kumar Yadav, and Mohit Sharma, "Applications of Artificial Intelligence and Machine Learning in Microbial Diagnostics and Identification," *Methods in Microbiology*, vol. 55, pp. 213-230, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[13] Yuandi Wu, and S. Andrew Gadsden, "Machine Learning Algorithms in Microbial Classification: A Comparative Analysis," *Frontiers in Artificial Intelligence*, vol. 6, pp. 1-22, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[14] Aakriti Jain et al., "An Explainable Machine Learning Pipeline for Prediction of Antimicrobial Resistance in Pseudomonas Aeruginosa," *Bioinformatics Advances*, vol. 5, no. 1, pp. 1-9, 2025. [CrossRef] [Google Scholar] [Publisher Link]

[15] Isaac Olatunji et al., "Artificial Intelligence Tools for the Identification of Antibiotic Resistance Genes," *Frontiers in Microbiology*, vol. 15, pp. 1-7, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[16] Autumn Arnold, Stewart McLellan, and Jonathan M. Stokes, "How AI Can Help us Beat AMR," *npj Antimicrobials and Resistance*, vol. 3, no. 1, pp. 1-15, 2025. [CrossRef] [Google Scholar] [Publisher Link]

[17] Tabish Ali, Sarfaraz Ahmed, and Muhammad Aslam, "Artificial Intelligence for Antimicrobial Resistance Prediction: Challenges and Opportunities Towards Practical Implementation," *Antibiotics*, vol. 12, no. 3, pp. 1-16, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[18] Yan Li et al., "Artificial Intelligence in Predicting Pathogenic Microorganisms' Antimicrobial Resistance: Challenges, Progress, and Prospects," *Frontiers in Cellular and Infection Microbiology*, vol. 14, pp. 1-13, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[19] Md Fakruddin, Reaz Mohammad Mazumdar, and Khanjada Shahnewaj Bin Mannan, "Predictive Microbiology: Modeling Microbial Responses in Food," *Ceylon Journal of Science (Biological Sciences)*, vol. 40, no. 2, pp. 121-131, 2011. [CrossRef] [Google Scholar] [Publisher Link]

[20] Timothy J. Rudge et al., "Computational Modeling of Synthetic Microbial Biofilms," *ACS Synthetic Biology*, vol. 1, no. 8, pp. 345-352, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[21] Yiru Jiang et al., "Machine Learning Advances in Microbiology: A Review of Methods and Applications," *Frontiers in Microbiology*, vol. 13, pp. 1-12, 2022. [CrossRef] [Google Scholar] [Publisher Link]